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This editorial summarizes a counterpoint American Associ-
ation for Thoracic Surgery debate opinion after the recent
Surgical Treatment for Ischemic Heart Failure (STICH) trial
published in The New England Journal of Medicine
(NEJM).1 That article may potentially alter treatment of con-
gestive heart failure (CHF) after ischemic dilated cardiomy-
opathy following myocardial infarction because the authors
conclude that adding surgical ventricular reconstruction
to reduce ventricular volume to coronary artery bypass graft-
ing (CABG) does not improve symptoms or exercise toler-
ance and fails to lower death rate or cardiac rehospitalization.
The original study examined the role of surgical ventric-
ular reconstruction or ‘‘surgical ventricular restoration’’
(SVR) in the dilated ventricles of patients with CHF with re-
gional scar after anterior myocardial infarction (Figure 1).
The adverse effects of dilatation are codified by White and
associates2 (Figure 2, A), who showed that increased ventric-
ular volume rather than altered ejection fraction became the
principal surrogate for mortality.
Dor3 showed that the SVR procedure excludes the underly-
ing culprit scar that causes stretch of compensating remote
muscle, identified similar regional noncontraction from either
aneurysm or akinetic segments that received thrombolysis or
angioplasty, and demonstrated that rebuilding left ventricular
(LV) size and shape toward normal improves cardiac efficiency
by restoring remote muscle function. The keynote finding of
similarly absent function in aneurysm without reperfusion (in
which the thinned scar collapses during venting) and akinesia
after reperfusion (in which the thick myocardium with inner
shell scar is covered by normal anterior myocardium that
does not collapse during venting) introduced a ‘‘new SVR tar-
get’’ and initiates ‘‘a learning curve’’ for procedure application.
SVR after CABG is based on an international database
registry of more than 5000 patients.3-5 This database
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CHF natural history studies6 and a CABG patient cohort
whose abnormal ejection fraction and class III/IV New
York Heart Association classification matched the RE-
STORE (Reconstructive Endoventricular Surgery, returning
Torsion Original Radius Elliptical Shape) group registry
cohort4,7 in National Heart, Lung, and Blood Institute
STICH grant application and the worldwide SVR registry.
A prospective randomized trial was designed for ‘‘evidence
based medicine’’ confirmation.
The 490 STICH trial patients requiring SVR did not show
survival or rehospitalization differences compared with the
greater than 5000 patient registry SVR database, thereby
raising this question: Is SVR an improper concept or did
the STICH trial have improper execution? The solution to
this question will determine whether STICH results provide
credible data that guide the treatment of patients with CHF.
We conclude that it did not, and this editorial supports this
deduction with trial evidence, reports casualties of the
STICH findings, poses new questions requiring answers,
and outlines future STICH report meaningful data analysis
that may properly respond to grant questions.
STICH TRIAL BACKGROUND AND EXECUTION
Initial planning required exclusion of the culprit scar with
nonviable regions confirmed by nuclear scans to avoid con-
fusion of hibernation within viable muscle. Two new steps
were required. First, participating cardiologists had to mea-
sure volume in trial entry patients with ejection fractions of
less than 35%, since differing volumes may have a similar
ejection fraction (Figure 2, B). Second, surgeons had to in-
cise the normal epicardium over underlying thick-walled
scar and reduce volume 30% below baseline levels. This
amount of volume reduction was selected because approxi-
mately 40% volume reduction (Table 1) was needed for
clinical improvement in prior SVR reports of more than
5000 patients. STICH measured volume in only 161 of
490 SVR patients and concluded that SVR is not better
than CABG. Unfortunately, no evaluation could be made
in 66% of SVR patients whose volume was not measured.
CHF severity reached grade III/IV (New York Heart Asso-
ciation) in only 49% of patients in the STICH cohort versus
approximately 67% in SVR registry reports,4 but post hoc
analysis can make such data-based comparisons.
Two entry criteria existed in the original protocol. First,
LV stroke volume index must be beyond 60 mL/m2. The
background volume requisite for surgical intervention
stemmed from the report by White and associates2 andrgery c November 2009
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from experience in aortic and mitral valve disease, where
progressive remodeling is not prevented if valve interven-
tions are made after end-systolic volume index (ESVI) ex-
ceeds 60 mL/m2 (Figure E1).18 Second, documentation of
greater than 35% akinesia from anterior wall necrosis was
necessary to show that the culprit scar caused remote muscle
dilatation that exceeded the 60 mL/m2 entry point.
These established primary objectives became altered in
2006 (http://clinicaltrials.gov/show/NCT00023595). Such
protocol deviation from approved entry criteria is possible
by executive decision by the principal investigator, can
only occur with approval of the National Institutes of Health
grant administration officer, and does not require approval
from the other trial participants. Investigational review
board notification of this change to other trial participants
is their responsibility. The new primary objective included
‘‘documented LV anterior wall dysfunction’’ if necrosis
and volume measurements were absent. Moreover, 13%
of patients had not had a myocardial infarction.
These primary goal changes introduced wall motion dis-
orders that may occur without necrosis after acute ischemia
or hibernation or may follow scar. Ischemic muscle without
scar may recover after CABG,19 but this cannot happen if
gadolinium magnetic resonance studies show greater than
50% of muscle is scarred.20 SVR has never been recommen-
ded in ventricles without scar, and applying SVR in hiber-
nating myocardium was not reported by Dor3 in more than
1000 patients or the 1198 RESTORE patient cohort, in
which all patients displayed electrocardiographic and imag-
ing evidence of large akinetic or dyskinetic scar with greater
than 60 mL/m2 ESVI measurements.
Echocardiography was used to measure LV volume in the
NEJM report but was evaluated in only 38% of STICH pa-
tients (212/490 CABG patients and 161/490 CABG and
SVR patients). Application of this echo-measuring technique
contradicts original and present protocol requirements (Sup-
plemental Data 1),where echocardiography is accepted duringThe Journal of Thoracic and Cscreening to measure ejection fraction, but 100% of consent-
ing patients required cardiac magnetic resonance (CMR) or
gated single photon emission computed tomography scans to
measure volume before and after SVR or CABG. Grant plan-
ning excluded 2-dimensional echocardiographic measurement
of volume because regional asynergy in ischemic disease
makes it unreliable for volume measurement,21 but this limita-
tion becomes offset by CMR 3-dimensional volume analysis.
LV volume was reduced by 19% in SVR patients to reach
a volume end point that reflects an inadequate repair as deter-
mined by the Surgery Therapy Committee, whose ‘‘accept-
able STICH procedure’’ guideline required a 30% ESVI
decrease at 4-month CMR measurement (Supplemental Data
2). Failure to achieve benchmark volume reduction differs
markedly from SVR values shown in Table 1, averaging
40% reduction and ranging between 30% and 58%. Conse-
quently, the STICH SVR procedure may have reflected a small
LV plication or limited intracavitary reconstruction.
Alteration of primary aim changes was suggested in
a 2005 trial editorial, ‘‘To STICH or not to STICH: We
Know the Answer, but Do We Understand the Question,’’22
which reached conclusions about questions the grant was as-
signed to test. Publication of this report led to an immediate
editorial in this Journal, ‘‘Questions and Answers About the
STICH Trial: A Different Perspective,’’23 in which answers
to original grant application goals were requested.
STICH FLAWS
The credibility of the STICH trial is questioned by flaws ad-
dressed in trial background above and execution sections by
FIGURE 1. Changes in LV size and shape after SVR. The elliptical normal
form (A) becomes spherical after anterior septal infarction (B). Size and
shape are returned toward a more normal elliptical configuration by placing
a patch to exclude the scar and returning nonscarred remote muscle back to
its conical form (C). Reprinted with permission from Buckberg G. Ventric-
ular Structure and surgical history. Heart Failure Rev. 2005;9:255-68.ardiovascular Surgery c Volume 138, Number 5 1061
Expert Commentary Buckberg and AthanasuleasFIGURE 2. A, Relationship between LV end-systolic volume and mortality. Note (1) that volume is in milliliters, not milliliters per square meter, so that the LV
end-systolic volume index would be twice this number if patient size were 2m2 and (2) that volume increase is a surrogate for increased mortality.2 B, Comparison of
prognosis in survivors and nonsurvivors in relationship to ejection fraction (solid line is at 35%) and LV end-systolic volume in milliliters. Note that lower LV end-
systolic volume at 35% ejection fraction is associated with reduced mortality in survivors compared with increased mortality in nonsurvivors when LV end-systolic
volume is higher at 35% ejection fraction.2 MI, Myocardial infarction; LVESV, left ventricular end-systolic volume. Reprinted with permission.2those listed below. First, all patients needed to have akinesia,
yet only 50% displayed this finding. Second, akinesia devel-
oped from regional necrosis of 35% of muscle, yet the report
fails to document this scar finding (Supplemental Data 3).
Third, CMR quantification of ventricular volume is needed
in all patients before and after SVR. Instead, 19% underwent
an invalid echocardiographic measurement, despite pretrial
contact showing CMR measurement capacity in all initial 50
trial centers (Supplemental Data 4). Fourth, 100% required
CMR volume measurement for trial entry, yet only 38%
(CABG and CABG plus SVR) had any form of volume mea-
surement. Fifth, SVR is indicated only if ESVI is beyond 60
mL/m2, yet volume measurements for SVR or CABG without
SVR candidates were not reported. Sixth, 30% reduction of
ESVI at 4 months by CMR study is required for acceptable
SVR procedure, but ESVI was lowered only 19% in the
33% of patients to demonstrate an inadequate end point. Sev-1062 The Journal of Thoracic and Cardiovascular Senth, the original trial included 50 centers, averaging approx-
imately 10 cases per center. Actually, 96 centers were used,
averaging approximately 5 procedures per center, so that Sur-
gical Therapy Committee outcome validation during accredi-
tation becomes a vital earmark before trial enrollment. Its
initial meeting outlined 10 cases per center and 5 per surgeon,
demonstrating the required 30% volume reduction. Instead,
no specification is shown that pretrial ESVI reduction fulfilled
trial eligibility criteria.
EVIDENCE BASED MEDICINE AND ROLE OF
EXPERIENCE
The hallmark of technical competence after a surgical pro-
cedure requires reaching goals that comply with yardsticks
of procedural success. For SVR, favorable clinical results
followed approximately 40% volume reduction below con-
trol levels in more than 1500 cases in 12 worldwide centersurgery c November 2009
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19% in 161 patients, and 96 centers were required to achieve
this end point. No volume studies occurred in 66% of pa-
tients and an invalid echo-based monitoring method was
used in the others. These limitations did not prevent STICH
end point interpretation that SVR should be abandoned be-
cause CABG achieved similar results. The ‘‘evidence based
medicine’’ analysis used to justify this conclusion does not
consider how results relate to evaluation of nonapproved
volume outcomes in only 33% of patients or how experi-
ence influences end point validity.
The 2005 editorial by one of us23 (G.D.B.) suggested poten-
tially inaccurate conclusions after volume reduction by com-
paring STICH to the 1976 Veterans Administration Hospital
CABG study24 of ischemic coronary artery disease re-
vascularization versus medical therapy. The 300 surgically
treated patients in 12 centers had 6% mortality (range
3%–12%) and closed conduits related to individual center ex-
perience. This contrasts with 1% mortality and superb graft
patency in a 1978 report of 1000 patients from the Cleveland
Clinic25 to demonstrate how experience based observations in-
fluence subsequent management. STICH trial inexperience
potential may relate to the learning curve of adequately reduc-
ing ventricular volume while doing a new procedure when
only about 5 cases per center are performed. Misguided results
may camouflage proper outcome analysis and impair correct
treatment in the same way that coronary revascularization
can be considered unsuccessful when only internal thoracic ar-
tery grafting is done without addressing a stenotic right coro-
nary artery, or concluding that antihypertensive drugs are
ineffective in studies that used inadequate medication dosages.
We believe that differences between STICH outcomes
and worldwide SVR data displaying greater volume reduc-
FIGURE 3. Overall hospital and late follow up mortality in patients with
congestive heart failure (CHF) after medical therapy, as reported by the
Framingham analysis,6 coronary revascularization (reprinted with permis-
sion),7 and surgical ventricular restoration (reprinted with permission).4The Journal of Thoracic and Ction indicate that the wrong operation, using the wrong vol-
ume measurement monitors, was done on the wrong patients
and resulted in the wrong conclusions. This outcome de-
prives cardiologists of understanding the potential role of
volume reduction to treat CHF from ischemic dilated cardio-
myopathy and demonstrates that the goals of evidence based
medicine were not achieved.
CASUALTIES OF STICH OUTCOMES
The first casualty of this report may be the increasing CHF
population with dilated hearts, which makes up approxi-
mately half of the CHF population,26 whereby misguided
conclusions may hamper proper treatment decisions. STICH
end points do not relate to the SVR procedure that requires
properly measuring necrosis and accurate ventricular vol-
ume before reducing volume more than 30% below preop-
erative levels.
Second, STICH may adversely affect cardiac surgery evo-
lution and nontransplant heart failure surgery by limiting de-
velopment of SVR, a unifying geometric treatment of dilated
cardiomyopathy from ischemic and nonischemic causes.
Moreover, SVR may link with LV assist devices to intro-
duce a ‘‘bridge to restoration’’ approach and ultimately
may create a surgical scaffold that marries this macroscopic
approach with cell therapy. The flawed database underlying
STICH findings may also limit future government interest in
funding other surgical trials.
The third casualty is scientific integrity, because measur-
ing volume rather than ejection fraction as the natural
TABLE 1. Left ventricular end-systolic volumes before and after
surgical ventricular restoration
ESVI (mL/m2)
Author(s) (year) No. of patients Preop. Postop. Reduction (%)
Di Donato et al8 (2009)
Type 1 56 83 35 48 (58)
Type 2 55 87 39 48 (55)
Type 3 67 96 57 39 (41)
Suma et al9 (2009) 76 123 74 49 (40)
Dor et al10 (2008) 104 93 51 42 (45)
Menicanti et al11 (2007) 301 173* 100* 73* (42)
O’Neill et al12 (2006) 135 120 77 43 (36)
Adams et al13 (2006) 8 92 59 33 (36)
Schreuder et al14 (2005) 9 92 45 47 (51)
Tulner et al15 (2006) 21 186* 101* 85* (46)
Yamaguchi et al16 (2005) 20 137 65 72 (53)
Mickleborough et al17
(2004)
41 97 65 32 (33)
Athanasuleas et al
(RESTORE group4)
(2004)
671 80.4 56.6 24 (30)
Jones et al (STICH
group1) (2009)
161 83 67 16 (19)
Data compiled by Hisayoshi Suma, MD. ESVI, End-systolic volume index. *End-sys-
tolic volume (mL), not indexed.ardiovascular Surgery c Volume 138, Number 5 1063
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lated hearts becomes impaired by STICH findings.
The fourth casualty may be health care cost of CHF treat-
ment, which may exceed $1 trillion per year in 2030
(Figure E2).27
STICH CONCLUSIONS AND QUESTIONS TO BE
ANSWERED
The following debate questions still require a proper re-
sponse. First, is ESVI measurement important in evaluating
and treating dilated cardiomyopathy? Second, why were in-
correct volume measurements used? Third, does CABG treat-
ment lead to improved function in scarred muscle? CABG is
used in the non-SVR group that does not exclude the scarred
segment. Fourth, where are viability measurements showing
35% regional necrosis in all included patients? Fifth, is there
confirmed validation of center–surgeon eligibility showing
greater than 30% volume reduction to comply with Surgical
Therapy Committee guidelines? Sixth, did STICH study is-
chemia (with or without hibernation) or postmyocardial in-
farction anterior scar? Seventh, why were the primary
objectives changed? Eighth, do STICH conclusions invali-
date the extensive SVR patient registry database?
STICH CONCLUSIONS AND MEANINGFUL END
POINTS
This analysis of STICH report flaws and conclusions sug-
gests the trial should retract the NEJM report or reanalyze
data to achieve meaningful results. The target goal must
(1) exclude all patients with invalid echocardiographic vol-
ume measurements, (2) include only patients in whom re-
gional nonviability of greater than 35% akinesia is
documented by nuclear medicine scans, (3) quantify all pa-
tients with greater than 30% volume reduction by CMR
study, and (4) report only patients with ‘‘acceptable’’ vol-
ume reduction by CMR at 4 months. The STICH trial must
address each of these questions because misguided STICH
conclusions contradict the role of augmented ventricular vol-
ume as the surrogate for the natural history of increasing
morbidity and mortality in dilated hearts.2,18 Without this ac-
tion, the STICH trial conclusions simply show that statisti-
cians can defy nature from a flawed database.
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Initial Evaluation of Patients for Eligibility for Random-
ization in Specified Stratum
Therefore, a 2-step process is proposed. The first step uses
the best available
LV assessment by either a contrast, gated single photon
emission computed tomography, or CMR ventriculogram
read at the clinical sites or a resting echocardiogram read
by the Echo Laboratory. This first step will identify patients
meeting LVEF entry criteria and
characterize the extent of anterior LV wall dysfunction
needed to evaluate SVR eligibility. After completion of
the first step, patients will be approached for informed
consent for randomization. The second step to confirm
the accuracy of these criteria by CMR or radionuclide
LV assessment proceeds only in consenting patients.
Supplemental Data 2
CABGþSVR Definition
The two criteria used by the Surgical Therapy Committee
to define the acceptable range of specific operative maneu-
vers essential to be considered an acceptable technical
SVR operation for the STICH Trial will be any ventricular* Unpublished information in the Supplemental Data sections is from the funded
STICH grant document, which is ‘‘publicly available’’ through the Freedom of In-
formation Act. (Bold type was added by the authors.)
The Journal of Thoracic and Cardreconstruction method that consistently results in (1) a low
operative mortality and (2) an average EF [ejection fraction]
increase of 10% and average LV end-systolic volume in-
dex decrease of 30% as assessed on the 4-month postop-
erative CMR measurement.
Supplemental Data 3
B.3. Rationale for Noninvasive Cardiac Imaging
Studies
The common clinical practice of not offering CABG to pa-
tients with LV dysfunction in regions found to be nonviable
on noninvasive studies is not justified by published data.
The STICH Trial proposes to use core laboratories for car-
diac magnetic resonance (CMR), echocardiography
(ECHO), and radionuclide (RN) studies to insure standard-
ization of testing practices and of data analysis for opera-
tional use of these studies in the STICH Trial.
Supplemental Data 4
Over 3 years, 50 clinical sites will recruit 2800 patients
with heart failure, left ventricular ejection fraction less
than 0.35, and CAD [coronary artery disease] amenable to
CABG. From http://clinicaltrials.gov/show/NCT00023595.iovascular Surgery c Volume 138, Number 5 1064.e1
Expert Commentary Buckberg and AthanasuleasFIGURE E1. Adverse effects on postoperative mortality after aortic valve
replacement (AVR)when LV end-systolic volume dimension exceeds 55 mm.
Similar adverse changes were reported after end-systolic volume index ex-
ceeded 55 mL/m2.18 LVD(S), Left ventricular diameter (systolic). Reprinted
with permission.181064.e2 The Journal of Thoracic and Cardiovascular SuFIGUREE2. Time -related cost of health care due to physician visits in the
congestive heart failure (CHF) population, when costs were estimated dur-
ing a time intervals between 2005 and 2030. Reprinted with permission.27rgery c November 2009
